119,230 Shares of Thermo Fisher Scientific Inc. $TMO Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 119,230 shares of the medical research company’s stock, valued at approximately $80,486,000.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. Bank of New York Mellon Corp acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth $1,974,561,000. Bank of America Corp DE purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,952,930,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Thermo Fisher Scientific by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after acquiring an additional 22,827 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Thermo Fisher Scientific during the second quarter valued at $1,122,351,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.7%

Shares of NYSE:TMO opened at $696.78 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The stock’s 50-day moving average is $654.87 and its 200-day moving average is $552.94. The company has a market cap of $257.63 billion, a P/E ratio of 36.75, a P/E/G ratio of 2.84 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the previous year, the firm earned $5.79 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TMO shares. Royal Bank Of Canada boosted their target price on Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a research note on Thursday, October 22nd. CLSA initiated coverage on Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Finally, DZ Bank cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $689.10.

Insiders Place Their Bets

In other news, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 76,199 shares of company stock valued at $45,896,780. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.